文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤患者有无缓解和进展的人群死亡率:来自荷兰黑色素瘤治疗登记处的数据

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.
PubMed 文献 · Eur J Cancer · 2023-01-17

该研究基于荷兰黑色素瘤治疗登记处2013至2019年诊断的5119例不可切除IIIC期或IV期黑色素瘤患者,采用多状态模型整合人群死亡率,并进行一年界标分析。结果显示,诊断后一年时仍存活且达完全缓解的患者,其5年黑色素瘤相关死亡概率随年龄增长而升高,<65岁为17.2%(95%CI 13.0-21.4),≥80岁为28.7%(95%CI 24.3-33.1);人群死亡率仅在年龄≥75岁且一年时达部分或完全缓解的老年患者中起较大作用。结论认为,尽管晚期黑色素瘤患者生存结局近十年有所改善,绝大多数患者仍死于黑色素瘤相关原因。

要点

  • 诊断后一年达完全缓解者5年黑色素瘤相关死亡概率<65岁为17.2%,≥80岁为28.7%。
  • 人群死亡率仅在≥75岁且一年时达部分或完全缓解的老年患者中起较大作用。
  • 尽管生存改善,绝大多数晚期黑色素瘤患者仍死于黑色素瘤相关原因。

核心结论

  • 尽管晚期黑色素瘤患者生存结局近十年有所改善,绝大多数患者仍死于黑色素瘤相关死亡。

研究设计与样本

  • 回顾荷兰黑色素瘤治疗登记处2013至2019年诊断的不可切除IIIC期或IV期黑色素瘤患者5119例。
  • 拟合整合人群死亡率的多状态模型,并进行一年界标分析评估各缓解状态后的结局。

主要发现

  • 诊断后一年时仍存活且达完全缓解的患者,5年黑色素瘤相关死亡概率随年龄增长而升高:<65岁为17.2%(95%CI 13.0-21.4),≥80岁为28.7%(95%CI 24.3-33.1)。
  • 人群死亡率仅在年龄≥75岁且诊断后一年时达部分或完全缓解的患者中起较大作用。

关键数值与推荐

  • 完全缓解者5年黑色素瘤相关死亡概率:<65岁17.2%(95%CI 13.0-21.4),≥80岁28.7%(95%CI 24.3-33.1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups. METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state. RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response. CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Breeschoten J, van den Eertwegh AJM, Hilarius DL, et al. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry. Eur J Cancer. 2023. PMID: 36773402. doi:10.1016/j.ejca.2023.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。